|Dr. David Young||Co- Founder, Chairman & CEO||N/A||N/A||1953|
|Mr. Patrick Lin||Co-Founder, Chief Bus. & Strategy Officer and Director||44.48k||N/A||1965|
|Dr. Sian E. Bigora||Co-Founder & Chief Devel. Officer||50.75k||N/A||1960|
|Ms. Wendy Guy||Co-Founder & Chief Admin. Officer||87.5k||N/A||1964|
|Mr. James H. Stanker||Chief Financial Officer||116.67k||N/A||1958|
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of drug products for the unmet medical needs. Its lead product candidate is PCS-499, an oral tablet that is in Phase IIa clinical trial for the treatment of necrobiosis lipoidica, an idiopathic disease of the dermis. The company was formerly known as Heatwurx, Inc. and changed its name to Processa Pharmaceuticals, Inc. in October 2017. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
Processa Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.